WillItSurvive
Pharma and healthcare groups · China

3SBio

3sbio.com ↗

Chinese biologics maker selling thrombocytopenia and anemia drugs, chasing PD-1/VEGF cancer drugs next.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: SSGJ-707 NSCLC data readout expected at ASCO, plus TPIAO/EPIAO NRDL reimbursement renewal talks
The call

3SBio's cash pile and hospital reach come from aging drugs losing ground, while its cancer-drug bet trails Akeso's already-proven rival.

3SBio makes and sells biologic drugs in China, with strong market share in blood disorders and anemia treatments that are hard to dislodge because they are already in 11,000 hospitals and covered by China's health insurance system. The real risk is that these old products are losing sales (down 9.3% last year without a one-time payment), and the company's new cancer drug is playing catch-up to a competitor called Akeso that already has a better version on the market and beat Merck's Keytruda head-to-head. The picture changes if 3SBio's new cancer drug can prove it works just as well as Akeso's when results come out in 2026, and if China's health insurance system keeps paying good prices for the old blood disorder drug when the contract renews.

Why
01
AI pressure: Insilico Medicine. AI-native drug discovery firms compress R&D timelines, letting rivals design fast-followers faster than 3SBio can. Could AI do the core job? Unlikely.
02
Bigger players: Akeso (ivonescimab, licensed to Summit Therapeutics). Akeso's PD-1/VEGF drug already beat Merck's Keytruda in a head-to-head trial, ahead of 3SBio's SSGJ-707 in the same race. Could a giant copy it? No, they are blocked.
03
What protects it. TPIAO and EPIAO still hold 66% and 42% of their China markets, sold through 11,000 hospitals under NRDL pricing rules.
What would change this call
TPIAO/EPIAO NRDL reimbursement renewal outcome, expected late 2026. A steep price cut would confirm legacy-product pricing power is weakening.
SSGJ-707 Phase 3/ASCO 2026 NSCLC data readout. Weak results versus Akeso's ivonescimab would show the growth bet is falling behind.
Mandi Inc. HK IPO completion and share distribution, mid-2026. Confirms the profitable consumer-health unit is being carved out, shrinking the core business.
Key numbers
  • FY2025 revenue RMB 17.7B, up 94.3% YoY (2025-12-31)
  • Core product revenue fell 9.3% YoY ex-Pfizer deal (2025-12-31)
  • Pfizer paid $1.25B upfront, up to $4.8B in milestones (2025-07-24)
Named risks
  • TPIAO/EPIAO NRDL reimbursement renewal expected late 2026 could cut pricing on largest legacy products. Severity: high
  • Core product revenue fell 9.3% YoY excluding one-time Pfizer licensing windfall. Severity: high
  • SSGJ-707 trails category leader Akeso's ivonescimab in the PD-1/VEGF bispecific race. Severity: medium
  • Mandi spin-off removes a profitable, high-growth consumer asset from the core company. Severity: medium
  • FY2025 earnings quality heavily dependent on a single lumpy Pfizer licensing payment. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Akesogaining onIvonescimab beat Keytruda on PFS in Phase 3 HARMONi-2, reported 2026-06-05, ahead of 3SBio's SSGJ-707
BioNTechgaining onAcquired Biotheus/BNT327 for $1B+ entering same PD-1/VEGF bispecific class, reported 2026-06-10
Insilico Medicinegaining onAI-native rival reported over $100M revenue on drug partnerships by mid-2026
CSPC Pharmaceutical GroupcontestingTrades at ~26x P/E vs 3SBio's ~7x as of 2026-04-08, both pivoting to innovative biologics
Merck (Keytruda)losing toPD-1/VEGF bispecific class (led by Akeso, contested by 3SBio) beat Keytruda head-to-head, 2026-06-05
Questions people ask
Is 3SBio profitable in 2026?
Yes. 3SBio reported FY2025 net profit of RMB 8.48 billion, up 305.8% YoY, on revenue of RMB 17.7 billion (up 94.3%), announced March 31, 2026. Most of the surge came from a RMB 9.43 billion Pfizer licensing payment; core product income actually fell 9.3% YoY.
Who owns 3SBio?
3SBio (HKEX: 1530) has no single controlling shareholder. Disclosed holders include TMF (Cayman) Ltd. (~22.8-23.9%) and Decade Sunshine/Mighty Decade entities. Pfizer took a $100 million equity stake as part of its July 24, 2025 licensing deal for SSGJ-707.
Who is 3SBio's biggest competitor?
In the PD-1/VEGF bispecific antibody race, Akeso is the acknowledged leader: its ivonescimab beat Merck's Keytruda on progression-free survival in the Phase 3 HARMONi-2 trial, reported June 5, 2026, putting 3SBio's rival drug SSGJ-707 in a fast-follower position.
Could AI replace 3SBio?
No. 3SBio's moat is physical: NRDL reimbursement listing, NMPA approvals, and distribution to over 11,000 hospitals, none of which AI replicates directly. But AI-native rival Insilico Medicine reported over $100 million in drug-partnership revenue by mid-2026, showing AI-driven discovery could compress rivals' R&D timelines.
What did 3SBio's Pfizer deal actually pay out?
Pfizer signed the SSGJ-707 licensing deal on May 19, 2025 and completed it July 24, 2025, paying $1.25 billion upfront plus a $100 million equity stake, with up to $4.8 billion in additional milestones, tiered double-digit royalties, and a separate $150 million option for China rights.
Why is 3SBio spinning off Mandi?
3SBio's shareholders approved distributing shares of consumer-health unit Mandi Inc. on April 23, 2026 with 99.995% support. Mandi, which holds an estimated 71% share of China's alopecia treatment market and posted RMB 390.3 million net profit in 2024, will list separately in Hong Kong.
Timeline
  • 2026-04-23Shareholders approve Mandi Inc. spin-off distribution with 99.995% support
  • 2026-04-08Report shows core product revenue fell 9.3% YoY excluding Pfizer licensing windfall
  • 2026-03-313SBio announces FY2025 results: revenue RMB17.7B, up 94.3% YoY
  • 2025-11-21Mandi files for Hong Kong IPO; 3SBio holds 87.16% stake pre spin-off
  • 2025-07-24Pfizer completes $1.25B licensing deal for SSGJ-707 bispecific antibody
  • 2025-05-19Pfizer signs exclusive licensing agreement with 3SBio for SSGJ-707
  • 2003-013SBio lists on HKEX, described as first Chinese biotech listed in Hong Kong
  • 1993-01Company founded as Shenyang Sunshine Pharmaceuticals by Lou Jing and Lou Dan
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources